359442-67-4

Basic information

• Product Name: N-(Allyloxy)-2-nitrobenzenesulfonaMide
• Synonyms: N-(Allyloxy)-2-nitrobenzenesulfonaMide;N-(Allyloxy)
• CAS NO: 359442-67-4
• Molecular Formula: C9H10N2O5S
• Molecular Weight: 258.2511
• Mol File: 359442-67-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 394.9±52.0 °C(Predicted)
• Appearance: /
• Density: 1.385±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 5.73±0.40(Predicted)
• CAS DataBase Reference: N-(Allyloxy)-2-nitrobenzenesulfonaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(Allyloxy)-2-nitrobenzenesulfonaMide(359442-67-4)
• EPA Substance Registry System: N-(Allyloxy)-2-nitrobenzenesulfonaMide(359442-67-4)

Safety Data

• Hazardous Substances Data: 359442-67-4(Hazardous Substances Data)

Usage

General Description

N-(Allyloxy)-2-nitrobenzenesulfonamide is a chemical compound with the molecular formula C9H10N2O5S. It is an allyl ether of 2-nitrobenzenesulfonamide, and it is used as a reagent in organic synthesis. N-(Allyloxy)-2-nitrobenzenesulfonamide is known for its nitro group, which makes it useful in various reactions such as nucleophilic aromatic substitution and palladium-catalyzed cross-coupling reactions. It is also used in the synthesis of pharmaceuticals, agrochemicals, and dyes. Additionally, it has been studied for its potential anti-inflammatory and anti-tumor properties, showing promise as a therapeutic agent in the future.

Upstream product

• 38945-21-0 O-allylhydroxylamine hydrochloride 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 

Relevant articles and documents

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

Multidrug resistant Gram-negative bacterial infections are an increasing public health threat due to rapidly rising resistance toward β-lactam antibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion of the resistance phenotype. β-Lactamase inhibitors (BLIs) can be administered in combination with β-lactam antibiotics to negate the action of the β-lactamases, thereby restoring activity of the β-lactam. Newly developed BLIs offer some advantage over older BLIs in terms of enzymatic spectrum but are limited to the intravenous route of administration. Reported here is a novel, orally bioavailable diazabicyclooctane (DBO) β-lactamase inhibitor. This new DBO, ETX1317, contains an endocyclic carbon-carbon double bond and a fluoroacetate activating group and exhibits broad spectrum activity against class A, C, and D serine β-lactamases. The ester prodrug of ETX1317, ETX0282, is orally bioavailable and, in combination with cefpodoxime proxetil, is currently in development as an oral therapy for multidrug resistant and carbapenem-resistant Enterobacterales infections.

HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS

The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R 2, R 3 and R 4 are described herein.